Eye Spy
Researchers create model for enzyme that plays role in
blindness
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New research from UNH advances the understanding — and ultimately treatment — of
a genetic mutation that causes vision disease and blindness.

MODEL BY UNH RESEARCHERS OF THE ACTIVATED COMPLEX OF THE PDE6
MOLECULE COMPLEX (GREEN AND CYAN) WITH TWO TRANSDUCIN SUBUNITS
(BLUE AND ORANGE) ASSOCIATED WITH THE PHOTORECEPTOR MEMBRANE.

In a recent paper published in the Journal of Biological Chemistry, UNH researchers
have reported the first structural model for a key enzyme, and its activating protein, that
can play a role in some genetically inherited eye diseases like retinitis pigmentosa and
night blindness.
“There has been substantial research on the biochemical pathway involving this
enzyme, known as PDE6, but defining atomic-level models is important for locating
PDE6 mutations in order to understand why they cause disease and how we can
develop new therapeutic interventions to manage retinal diseases,” says Rick Cote,
director of the Center of Integrated Biomedical and Bioengineering Research and
principal investigator on the study.
Vision starts in the photoreceptor cells of the retina which contains rods, responsible for
low light vision, and cones, which are active in brighter light and capable of color vision.
When light is absorbed by the rods and cones, it triggers a pathway which activates the
enzyme phosphodiesterase 6, or PDE6. This generates a nerve impulse to the brain
that ultimately results in visual perception. Some genetically inherited eye diseases are
caused by mutations to PDE6, or its activating protein, transducin, that can lead to
disruptions of normal vision or even total blindness

"Defining atomic-level models is important for locating
PDE6 mutations in order to understand why they cause
disease and how we can develop new therapeutic
interventions to manage retinal diseases.”
In the study, the researchers reported how they were able to use chemical cross-linking
combined with mass spectrometric analysis to resolve the structure of PDE6 in its
nonactivated and transducin-activated states. This approach permitted visualization of
flexible regions of individual PDE6 catalytic and inhibitory subunits that were poorly
resolved in previous work as well as the overall molecular architecture of the activated
protein complex.
“Determining the structure of these visual signaling proteins has always been a
challenge because of their complexity,” says Michael Irwin, doctoral student in
biochemistry and lead author. “Having detailed structural information about how PDE6
is activated by transducin will help us understand the molecular causes of visual
disorders and blinding diseases resulting from mutations in these proteins.”
Current medical treatment for such genetically inherited retina diseases may include
gene therapy or drugs meant to inhibit the disease process. However, they are not
always successful in restoring the balance of PDE6 and preventing blindness. Scientists
believe that knowing the molecular structures of these visual signaling proteins and how
they interact with each other can offer clues for the development of new drugs to both
restore vision and prevent blindness.

This research was funded by the National Eye Institute, the National Institute of General
Medical Sciences, the National Institute of Child Health and Human Development, the
National Science Foundation and the UNH Research Office.
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